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Objectives: To assess the performance of the (1,3)-β-D-glucan (BDG) detection assay in a 
large cohort of patients with suspected candidemia who were admitted to non-intensive care 
unit hospital wards.
Methods: This observational, retrospective cohort study was conducted in a 1,100-bed university 
hospital in Rome, where an infectious disease consultation team has been operational. Two groups 
of patients were included in the analysis: Group 1, patients with Candida bloodstream infection 
(BSI) who had at least one BDG test performed ±48 hours from the first positive blood culture 
(Candida BSI Group) and Group 2, patients with risk factors for candidemia who had at least 
one BDG test but had negative blood cultures (Control Group). Both Group 1 and Group 2 did 
not receive prior antifungal therapy. Different BDG cutoff values were considered: 80, 200, 300, 
400, and ≥500 pg/mL. Sensitivity, specificity, positive predictive value (PPV), negative predic-
tive value (NPV), and area under the receiver operating characteristic curve were calculated.
Results: A total of 1,296 patients were studied. Of them, 100 patients (candidemic) were in 
Group 1 and the remaining 1,196 patients (controls) were in Group 2. There were no differences 
in demographic characteristics between patients of the two groups. According to the above 
cutoff values, sensitivity (%) and specificity (%) of the BDG assay ranged from 91 to 60.7 and 
87.7 to 97.8, respectively, whereas the PPV (%) and NPV (%) ranged from 38.2 to 68.3 and 
99.1 to 97.0, respectively.
Conclusion: Serum BDG has a very high NPV in a population with~10% prevalence of can-
didemia. This NPV may support decisions to discontinue antifungal therapy in those patients 
who were empirically treated because of the suspect of candidemia.
Keywords: β-glucan, candidemia, Candida, bloodstream infections, antimicrobial stewardship, 
diagnostic biomarkers
Background
Bloodstream infections (BSIs) due to Candida spp. are a frequent clinical condition 
in hospitalized patients, which significantly contributes to their morbidity and mortal-
ity. Candida spp. account for 9% of all BSIs and up to 25% of BSIs associated with 
central venous catheter (CVC).1 The mortality rate of candidemia has been found to 
be high in the past two decades, being estimated as 5%–71%.2–4
The gold standard method for the diagnosis of Candida BSIs are blood cultures, 
which usually take about 2 days to yield positive results, but their sensitivity is as low 
as 50%.5,6 Many studies have investigated the risk factors for candidemia; however, the 
list of risk factors is large7 and most of the hospitalized patients shared at least one of 
these risk factors. Several scores have been evaluated to help in identifying patients at 
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the highest risk of Candida BSIs, but they are often difficult 
to calculate in nonintensive care unit (non-ICU) settings.8,9 
Therefore, when suspecting candidemia, criteria that allow 
physicians to start antifungal therapy remain controversial. 
Anyway, appropriate antifungal therapy, especially when 
early administered, was seen to correlate with a better 
survival.10
To reduce unnecessary antifungal empirical therapy, 
many efforts have been devoted to improve the diagnostic 
sensitivity of culture-independent tests.11 Among them, the 
T2Candida nanodiagnostic panel (T2 Biosystems, Lex-
ington, MA, USA) and a (1,3)-β-D-glucan (BDG) assay 
(Fungitell; Associates of Cape Cod, East Falmouth, MA, 
USA) were cleared by the US Food and Drug Administra-
tion for the diagnosis of candidemia and invasive fungal 
infections, respectively.12 As Bayesian biomarkers, these 
tests assign a probability of infection; thence, management 
decisions based on test results will be left to the judgment 
of physicians .12 However, both molecular and nonmo-
lecular diagnostic tests could be a strong support for more 
rapidly identifying patients who should start empirical 
antifungal treatment.13
With regard to BDG, studies conducted in the ICU 
setting showed that BDG assay can be used to specifically 
improve the early discrimination between patients with 
culture-documented candidemia and patients with suspected 
candidemia.14–16 Particularly, high negative predictive values 
(NPVs) of BDG (≥97%) in patients at risk for candidemia12 
could be useful for an early discontinuation of antifungal 
therapy. To the best of our knowledge, very few studies were 
conducted in non-ICU wards until now. In the present study, 
we aimed to assess the performance of the BDG assay in a 
large cohort of patients with suspected candidemia admitted 
to non-ICU hospital wards.
Methods
This observational, retrospective, case–control study was 
conducted at a 1,100-bed university hospital (Fondazione 
Policlinico Universitario A. Gemelli IRCCS, Università 
Cattolica del Sacro Cuore, Rome, Italy), where an inpatient 
infectious disease consultation team (IDCT) has operated 
since November 2012. The team is made up of four infec-
tious disease specialists. Any hospital physician operating in 
medical and surgical units can request an infectious disease 
consultation via the hospital’s computerized information 
system. The IDCT takes charge of patients at the bedside 
within 24 hours of the request. The service is not active 
in Hematology unit and ICU, so patients from these wards 
were not included in the study. Follow-up consultations are 
provided only after a request by the ward physician. An 
alert system for blood cultures is active from Monday to 
Saturday: a microbiologist informs the in-charge infectious 
disease specialist of any positive blood culture at the time of 
identification. Data from every consultation is daily added 
into a standardized database.
To calculate the sensitivity, specificity, positive predic-
tive value (PPV), and NPV of BDG assay, we identified two 
groups of people. Group 1 consisted of all patients with 
culture-documented candidemia who had at least one BDG 
test performed ±48 hours from the first positive blood culture 
and had never been treated before with antifungal therapy 
(ie, Candida BSI Group). Group 2 consisted of all patients 
with at least one risk factor for candidemia (ie, surgery in 
the previous 30 days, presence of CVC, antibiotic therapy in 
the last 90 days, dialysis, or an immunosuppression status) 
who had at least one BDG test performed but had negative 
blood cultures and had never been treated with antifungal 
therapy (ie, Control Group). All consecutive patients from 
January 2013 to November 2016 who met one of the two 
study group criteria were enrolled in Candida BSI Group 
or Control Group, respectively. Candida BSI was defined as 
the isolation of Candida spp. in at least one blood culture 
drawn from a patient. Candida catheter-related (CR)-BSI 
was defined when the time of positivity of blood culture 
from a peripheral vein was at least 2 hours more than time 
of positivity of blood culture from a CVC.17 Septic shock 
at the time of blood culture was also assessed. During the 
study period, the rate of Candida BSIs was 16% of all BSIs 
identified at our Institution.
The Fungitell assay (Associates of Cape Cod) was used 
for BDG measurement. BDG results were evaluated using 
different cutoff values: 80, 200, 300, 400, and ≥500 pg/mL. 
Candida spp. were isolated from blood using the Bactec 
(Thermo Fisher Scientific, Waltham, MA, USA) or BacT/
Alert (bioMérieux, Marcy l’Etoile, France) system and 
were identified by matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry.18 For clinical use, the 
BDG test was considered positive if BDG level was above 
the manufacturer’s recommended cutoff (80 pg/mL).
No informed consent was required because the activity 
of the IDCT constitutes routine clinical practice and only 
anonymized data were analyzed. The need for informed con-
sent was waived by the local Institutional Review Board of 
the Fondazione Policlinico Universitario A. Gemelli IRCCS, 
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Performance of the (1,3)-β-D-glucan detection assay
statistical analysis
Demographic, epidemiological, and clinical characteris-
tics of patients in Candida BSI Group were compared to 
those of Control Group. Normally distributed values were 
expressed as mean (±SD), and nonnormally distributed 
values as median (interquartile range). Chi-squared or 
Fisher’s exact test was used to compare the distribution of 
categorical variables, and Student’s t-test or Mann–Whitney 
U test was used to compare quantitative variables. A two-
sided P-value <0.05 was considered statistically significant. 
To calculate the diagnostic performance of BDG assay, the 
sensitivity, specificity, PPV, and NPV of the test and their 
95% CIs were calculated.
The 30-day crude mortality rate (death from any cause 
within 30 days from the first positive blood cultures in Can-
dida BSI Group and from the BDG assay in Control Group) 
was also calculated for both the study groups stratifying 
for the BDG result. The discriminatory power of the BDG 
assay was assessed by the area under the receiver operating 
characteristic (ROC) curve (AUROC) calculation. All statisti-
cal analyses were performed using SPSS 17.0 (SPSS Inc., 
Chicago, IL, USA).
Results
We identified 1,296 patients with at least one BDG result, of 
which 100 patients were in Candida BSI Group and 1,196 
patients were in Control Group. The mean age was 65 (±20) 
years, and 774 patients (59.7%) were males. Approximately 
two-thirds of the study population was admitted to Medicine 
wards and a third to General Surgery (and other surgical 
specialties) wards. The clinical characteristics of the study 
population are shown in Table 1. Patients in Candida BSI 
Group were more likely to have septic shock (9.1% vs 0.7%; 
chi-squared test, P<0.001). Risk factors for Candida infec-
tion, such as the presence of CVC or a previous hospital stay, 
were significantly more common in Candida BSI Group. 
In 38 cases (38%) of candidemia, a CR-BSI was identified. 
Sixty-two percent of Candida BSIs were caused by Candida 
albicans, 24.2% by Candida parapsilosis, and 5% by Can-
dida glabrata. The 30-day mortality rate was significantly 
Table 1 characteristics of the study population








Mean age (years)±sD 64.7±20.3 66.9±18.6 64.5±20.5 0.27















Previous hospitalization 489 (37.7) 55 (55.6) 434 (36.3) <0.001
Risk factors for Candida infection
central venous catheter 426 (32.9) 82 (82.8) 344 (28.7) <0.0001
Previous antibiotic use 415 (32.0) 38 (38.4) 377 (31.5) 0.16
chemo- or radiotherapy 70 (5.4) 8 (8.1) 62 (5.2) 0.22
Dialysis 49 (3.8) 1 (1.0) 48 (4.0) 0.13
surgery in the 30 days before 157 (12.1) 1 (1.0) 156 (13.0) 0.001
Comorbidities
Diabetes 156 (12.0) 6 (6.1) 150 (12.5) 0.07
solid organ transplant 46 (3.5) 1 (1.0) 45 (3.8) 0.25
solid organ cancer 316 (24.4) 30 (30.3) 286 (23.9) 0.15
Dialysis 49 (3.8) 1 (1.0) 48 (4.0) 0.17
cirrhosis 57 (4.4) 7 (7.1) 50 (4.2) 0.20
chronic renal failure 144 (11.1) 8 (8.1) 136 (11.4) 0.40
Obesity 42 (3.2) 2 (2.0) 40 (3.3) 0.77
septic shock 17 (1.3) 9 (9.1) 8 (0.7) <0.001
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Table 2 Diagnostic performance of the BDg detection assay at different cutoff values
BDG test performance Values of BDG cutoff (pg/mL) used to calculate the indicated parameters
80 200 300 400 >500
sensitivity (%) 91.0 76.4 68.5 64.0 60.7
Specificity (%) 87.7 94.9 96.1 97.2 97.8
PPV (5) 38.2 53.5 57.5 64.0 68.3
nPV (5) 99.1 98.1 97.5 97.2 97.0
area under the ROc curve (95% cI) 0.89 (0.86–0.93) 0.86 (0.81–0.90) 0.82 (0.77–0.88) 0.81 (0.75–0.86) 0.79 (0.73–0.85)
Abbreviations: BDg, (1,3)-β-D-glucan; nPV, negative predictive value; PPV, positive predictive value; ROc, receiver operating characteristic.
Figure 1 area under the ROc curve showing the diagnostic sensitivity and 
specificity of the BDG detection assay.















higher in Candida BSI Group than in Control Group (30.3% 
vs 8.6%; chi-squared test, P<0.0001).
The mean of risk factors for candidemia was 0.86 (SD 
0.80). It was higher in people with positive BDG result (1.13 
[SD 0.84]) than in people with negative BDG result (0.80 
[SD 0.78]) (t-test, P<0.001). Only few patients (33, 2.5%) 
had three or more risk factors.
Using the 80 pg/mL cutoff value, a negative BDG result 
was found in nine (9%) of the 100 patients in Candida BSI 
Group, and in 1,049 (87.7%) of the 1,196 patients in Control 
Group. Only one of the nine patients with candidemia and 
negative BDG result had a BSI due to C. parapsilosis. The 
number of patients who had candidemia despite a negative 
BDG result was nine out of 1,058 (0.85%). In Control Group, 
34 (2.8%) patients had a BDG cutoff of ≥500 pg/mL. The 
sensitivity, specificity, PPV, and NPV of BDG test at different 
cutoff values are shown in Table 2. Time to BDG test did not 
correlate with the BDG value (linear regression, P=0.34).
With the increase of the cutoff value (80 to ≥500 pg/
mL), sensitivity of the biomarker decreased (from 89.8% to 
60.7%), whereas specificity remained >90% (up to 97.8%). 
The AUROC was ≥0.79 for all the cutoff values of BDG. 
Figure 1 shows the AUROC calculated using the cutoff of 
80 pg/mL as a diagnostic value.
Overall, the 30-day mortality of patients with a positive 
BDG result was higher than that of patients with a negative 
BDG result (19.8% vs 8.0%; chi-squared test, P<0.001). Only 
in Control Group, patients with a positive BDG result trended 
toward higher mortality compared to patients with a negative 
BDG result (12.2% vs 8.0%; chi-squared test, P=0.08). In 
particular, 18 of 34 patients with a positive BDG result died 
within 30 days without starting antifungal therapy (mean of 
survival, 7.9 days [SD 7.3]), and six of these patients had a 
BDG value of ≥500 pg/mL (mean of survival, 8 days [SD 8.6]).
Discussion
In the present study that involves non-ICU patients, we show 
that the BDG detection assay (cutoff, 80 pg/mL) had a high 
NPV (>99%), thus confirming the good accuracy of the assay 
for identifying patients without Candida BSI. Our findings 
may support strategies aimed at discontinuing empirical 
antifungal therapy when BDG results are negative.
Several studies have evaluated the performance of BDG 
assay in different clinical contexts. Studying a small popula-
tion of ICU patients in 2011, Posteraro et al showed that the 
NPV of BDG was higher (98.7%) than that of Candida score 
(≥3, 97.2%) or colonization index (≥0.5, 91.7%).14 In a study 
on 89 surgical ICU patients with abdominal candidiasis, Tis-
sot et al found an NPV of 78%,15 whereas in a study on 100 
patients, most of them admitted to ICU, the NPV of BDG 
was 86%–90%.16 Giacobbe et al recently found a high PPV 
(96%) and a high NPV (93%–95%) when using both BDG 
and procalcitonin for the diagnosis of Candida BSI in ICU 
patients.19 In two meta-analyses,20,21 the AUC for BDG was 
0.88 and 0.84. In a study on application of mass spectrometry 
in diagnosis of fungal infections, Mery et al showed that 
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Performance of the (1,3)-β-D-glucan detection assay
ments BDG detection.22 Although it is difficult to compare 
our results with those of previous reports because of differ-
ences in the study design, invasive candidiasis definition, 
patient populations, and negative controls, the NPV of BDG 
was always excellent. Unlike previous studies, we included 
a very large population and, to maximize the stringency of 
the study, we used as controls those patients with risk factors 
for candidemia but who did never receive antifungal therapy. 
Some authors highlighted that BDG test result could be more 
frequently negative in patients with C. parapsilosis BSI.23 
However, in our population only one of nine patients with a 
negative BDG result had a C. parapsilosis BSI.
The pretest probability in the present cohort was 8%, 
slightly lower than in other published cohorts. This is prob-
ably due to the non-ICU setting of the study. It should be 
considered that in extremely high-risk patients (such as those 
in ICU with >30% of pretest likelihood), NPV could be lower 
than that in our study.
Confirming previously published results, the role of BDG 
in the diagnosis of Candida BSI is probably less relevant than 
excluding it. In fact, sensitivity of BDG is suboptimal, rang-
ing from 77% to 91%.24,25 In our study, even at the highest 
cutoff (≥500 pg/mL), sensitivity was 61%. BDG can be found 
in many biological compounds, and several factors, such as 
antimicrobial therapy, nutritional intake, albumin, surgical 
sponges and/or gauze, and hemodialysis products, are known 
to be possible causes of false positivity.26 According to some 
studies, even systemic bacterial infections may result in false-
positive BDG results.27 However, since 18 patients in Control 
Group (1.5%) died within 30 days, we cannot definitively 
rule out the presence of Candida infection considering that 
the blood culture sensitivity is suboptimal.28
Empirical antifungal therapy accounts for about 40% 
of antifungal use.16,29–31 Hence, efforts should be focused 
on improving the diagnostic sensitivity and specificity of 
available tests. Considering the well-recognized limitations 
of blood cultures in diagnosing invasive candidiasis,32,33 an 
accurate and rapid biomarker could be very useful in treatment 
decision for patients with suspected candidemia. BDG results 
can be available in 12–24 hours. Considering the NPV of our 
study, clinicians could stop treatment based on negative result 
rapidly but not before the results of negative blood cultures 
are known (if possible, never before the first 48–72 hours). 
Determination of BDG is costly, and there are no cost-benefit 
studies of BDG determination in non-ICU patients. For these 
reasons, in our opinion, its use should be limited to profes-
sionals with a great expertise in the infectious diseases field 
and the management of invasive fungal infections.
People with positive BDG result had a higher mortality in 
our study. This result confirms previous findings.34–36 It should 
be noted that the mean of survival in people with positive 
BDG result within the Control Group was very short. We do 
not know whether an earlier initiation of empirical antifungal 
therapy in these patients could have modified the survival.
The study has several limitations. First, since it is a 
monocentric study, the generalizability of the results must be 
demonstrated. Second, this is not an intervention study. The 
real efficacy of a BDG-based strategy to control overtreat-
ment with antifungal regimens is not widely demonstrated. 
Unfortunately, only retrospective studies were published 
on the use of BDG in daily practice and almost all of them 
were done in ICU patients. Third, the usefulness of BDG in 
uncertain Candida infections is unknown. Fourth, no data 
on invasive candidiasis in the absence of candidemia (ie, 
abdominal candidiasis) are reported and the performance of 
BDG in such a situation was not evaluated.
Conclusion
The NPV value of BDG result was optimal even in a real-
world setting, possibly supporting prospective studies on 
discontinuation of empirical antifungal therapy when BDG 
results are negative. The control of overtreatment is a corner-
stone of antimicrobial stewardship: cost-effectiveness studies 
on the use of BDG in the context of a suspected invasive 
candidiasis are strongly warranted as well as studies on a 
BDG-based therapeutic approach.
Disclosure
The authors report no conflicts of interest in this work.
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